



GNI Ranked Number Six in the 2007 Deloitte FAST 50

Tokyo October 11, 2007 — GNI Ltd (TSE Mothers Code: 2160), a leading biopharmaceutical company in Japan and China, announced that it has been ranked number six in the 2007 Deloitte Technology Fast 50 Japan, a ranking of the 50 fastest growing technology companies in Japan, by global accounting firm Deloitte Touche Tohmatsu.

<http://www.tohmatsu.co.jp/news/2007/press1011.shtml>

“I am delighted with the company’s Fast 50 ranking. This result confirms that we have achieved rapid growth over the past three years and we look forward to building on this to achieve further growth in the future,” said Dr. Ying Luo, Chief Executive Officer of GNI.

The “Technology Fast 50 Japan” is a program that ranks the fastest-growing technology companies in the TMT industry (Technology, Media, and Telecommunications) based on average percentage revenue growth over three years. The Japan program is part of the global “Deloitte Fast 500 Asia Pacific”, which ranks the 500 fastest-growing high-tech companies based in the Asia Pacific, North America, and the EMEA region.

For further inquiries

Tetsuya Yoshikawa

Tel: +81 (03) 3580-0751

Ying Luo

Tel: +86 1381-769-8961

Notes to editors

About GNI

Founded in 2001, GNI is a clinical-stage international drug development company with headquarter in Japan and major operation China. GNI has successfully mapped gene regulatory networks via a complex process of reverse-engineering. Furthermore, GNI has developed the technology required to apply this data to drug development and discovery. In June 2005, GNI acquired Shanghai Genomics, which operates an integrated drug discovery and development platform in Shanghai, China. The combined strength of GNI and Shanghai Genomics has resulted in research collaboration with major international pharmaceutical companies. For further information, please visit www.gene-networks.com and www.shanghai-genomics.com.